Shannon D Sullivan1,2,3,4,5, Mark S Nash1,2,3,4,5, Eshetu Tefara1,2,3,4,5, Emily Tinsley1,2,3,4,5, Suzanne Groah1,2,3,4,5. 1. Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Ave, Building 22, Room 3373, Silver Spring, MD 20993. 2. Departments of Neurological Surgery and Physical Medicine & Rehabilitation, University of Miami Miller School of Medicine, Miami, FL. 3. Department of Biostatistics and Bioinformatics, Medstar Health Research Institute, Hyattsville, MD. 4. Department of Rehabilitation Medicine, Medstar National Rehabilitation Hospital, Washington, DC. 5. Department of Rehabilitation Medicine, Medstar National Rehabilitation Hospital, and Department of Rehabilitation Medicine, Medstar Georgetown University Hospital, Washington, DC.
Abstract
BACKGROUND: We reported previously that young men with chronic spinal cord injury (SCI) have a greater prevalence of testosterone deficiency compared with an age-matched, healthy control population. Young men with SCI also are at increased risk for developing cardiometabolic dysfunction after injury. It is unclear whether testosterone deficiency is associated with heightened cardiometabolic risk in men with SCI. OBJECTIVE: To investigate associations among levels of testosterone in young men with chronic SCI and surrogate markers of cardiometabolic risk. DESIGN: Secondary cross-sectional analysis. SETTING: Rehabilitation research centers in Washington, DC, and Miami, Florida. PARTICIPANTS: Men (n = 58) aged 18-45 years with chronic (≥1 year), motor complete SCI without comorbidities or use of testosterone therapy. METHODS: Plasma concentrations of testosterone, lipids, inflammatory markers (C-reactive protein and interleukin-6), percent hemoglobin A1c, glucose, and insulin were measured in a fasting state using standard assays. A 2-hour oral glucose tolerance test and Framingham Risk Score were assessed for each subject. Body composition was assessed by dual X-ray absorptiometry scan. MAIN OUTCOME MEASUREMENTS: Surrogate markers of cardiometabolic risk among men based on the level of total testosterone (TT; ≤300, 301-500, or >500 ng/dL) and free testosterone (fT; ≤9 or >9 ng/dL). Comparisons were made between men with normal and low TT or fT. RESULTS: Framingham Risk Score was significantly greater in men with low fT (P < .05). Percent body fat (P < .05) and waist-to-hip ratio (P < .05) but not body mass index (P > .08), were greater in men with low TT or low fT. Men with low TT or low fT had lower high-density lipoprotein cholesterol levels (P < .05) without differences in fasting triglycerides (P > .1) or low-density lipoprotein cholesterol (P > .07). Men with low TT had greater levels of inflammatory markers C-reactive protein (P < .05) and interleukin-6 (P < .05). Men with low TT or low fT had greater fasting glucose (P < .05) and greater insulin resistance (P < .04), without differences in percent hemoglobin A1c (P > .8). CONCLUSIONS: In young men with chronic SCI who undergo an accelerated aging process postinjury, hypogonadism is associated with an unfavorable cardiometabolic risk profile. Further research is needed to determine whether a causal relationship exists between hypogonadism and heightened cardiometabolic risk in men with SCI and whether routine screening for testosterone deficiency is warranted in this population. LEVEL OF EVIDENCE: IV.
BACKGROUND: We reported previously that young men with chronic spinal cord injury (SCI) have a greater prevalence of testosterone deficiency compared with an age-matched, healthy control population. Young men with SCI also are at increased risk for developing cardiometabolic dysfunction after injury. It is unclear whether testosterone deficiency is associated with heightened cardiometabolic risk in men with SCI. OBJECTIVE: To investigate associations among levels of testosterone in young men with chronic SCI and surrogate markers of cardiometabolic risk. DESIGN: Secondary cross-sectional analysis. SETTING: Rehabilitation research centers in Washington, DC, and Miami, Florida. PARTICIPANTS: Men (n = 58) aged 18-45 years with chronic (≥1 year), motor complete SCI without comorbidities or use of testosterone therapy. METHODS: Plasma concentrations of testosterone, lipids, inflammatory markers (C-reactive protein and interleukin-6), percent hemoglobin A1c, glucose, and insulin were measured in a fasting state using standard assays. A 2-hour oral glucose tolerance test and Framingham Risk Score were assessed for each subject. Body composition was assessed by dual X-ray absorptiometry scan. MAIN OUTCOME MEASUREMENTS: Surrogate markers of cardiometabolic risk among men based on the level of total testosterone (TT; ≤300, 301-500, or >500 ng/dL) and free testosterone (fT; ≤9 or >9 ng/dL). Comparisons were made between men with normal and low TT or fT. RESULTS: Framingham Risk Score was significantly greater in men with low fT (P < .05). Percent body fat (P < .05) and waist-to-hip ratio (P < .05) but not body mass index (P > .08), were greater in men with low TT or low fT. Men with low TT or low fT had lower high-density lipoprotein cholesterol levels (P < .05) without differences in fasting triglycerides (P > .1) or low-density lipoprotein cholesterol (P > .07). Men with low TT had greater levels of inflammatory markers C-reactive protein (P < .05) and interleukin-6 (P < .05). Men with low TT or low fT had greater fasting glucose (P < .05) and greater insulin resistance (P < .04), without differences in percent hemoglobin A1c (P > .8). CONCLUSIONS: In young men with chronic SCI who undergo an accelerated aging process postinjury, hypogonadism is associated with an unfavorable cardiometabolic risk profile. Further research is needed to determine whether a causal relationship exists between hypogonadism and heightened cardiometabolic risk in men with SCI and whether routine screening for testosterone deficiency is warranted in this population. LEVEL OF EVIDENCE: IV.
Authors: Shehzad Basaria; Andrea D Coviello; Thomas G Travison; Thomas W Storer; Wildon R Farwell; Alan M Jette; Richard Eder; Sharon Tennstedt; Jagadish Ulloor; Anqi Zhang; Karen Choong; Kishore M Lakshman; Norman A Mazer; Renee Miciek; Joanne Krasnoff; Ayan Elmi; Philip E Knapp; Brad Brooks; Erica Appleman; Sheetal Aggarwal; Geeta Bhasin; Leif Hede-Brierley; Ashmeet Bhatia; Lauren Collins; Nathan LeBrasseur; Louis D Fiore; Shalender Bhasin Journal: N Engl J Med Date: 2010-06-30 Impact factor: 91.245
Authors: William A Bauman; Michael F La Fountaine; Christopher M Cirnigliaro; Steven C Kirshblum; Ann M Spungen Journal: J Spinal Cord Med Date: 2014-06-26 Impact factor: 1.985
Authors: A Katz; S S Nambi; K Mather; A D Baron; D A Follmann; G Sullivan; M J Quon Journal: J Clin Endocrinol Metab Date: 2000-07 Impact factor: 5.958
Authors: W A Bauman; C M Cirnigliaro; M F La Fountaine; A M Jensen; J M Wecht; S C Kirshblum; A M Spungen Journal: Horm Metab Res Date: 2011-06-29 Impact factor: 2.936
Authors: Racine R Emmons; Carol Ewing Garber; Christopher M Cirnigliaro; Steven C Kirshblum; Ann M Spungen; William A Bauman Journal: Ultrasound Med Biol Date: 2011-03-25 Impact factor: 2.998
Authors: Mary J Clark; Laura H Schopp; Micah O Mazurek; Isabella Zaniletti; Andrew B Lammy; Thomas A Martin; Florian P Thomas; Michael E Acuff Journal: Am J Phys Med Rehabil Date: 2008-09 Impact factor: 2.159
Authors: Marcus Lind; Jaakko Tuomilehto; Matti Uusitupa; Olle Nerman; Johan Eriksson; Pirjo Ilanne-Parikka; Sirkka Keinänen-Kiukaanniemi; Markku Peltonen; Aldina Pivodic; Jaana Lindström Journal: PLoS One Date: 2014-10-06 Impact factor: 3.240
Authors: Jacob A Goldsmith; Raymond E Lai; Ryan S Garten; Qun Chen; Edward J Lesnefsky; Robert A Perera; Ashraf S Gorgey Journal: Front Physiol Date: 2022-02-10 Impact factor: 4.566